Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Blis Technologies Limited Capital/Financing Update 2025

Jul 1, 2025

66168_rns_2025-07-02_09865289-6b6c-4b7a-a146-a53bf681ebf6.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [157 x 58] intentionally omitted <==

2 July 2025

Patent issue settled and new 5 year agreement with BSP

On 14 October 2024, based on the information we had on hand at the time, we advised the market about a breach of contract by Bluestone Pharma GmbH (BSP) and Lactosan GmbH & Co. KG (Lactosan).

Since then, BSP and BLIS Technologies Limited (BLIS) have been progressing communications in relation to the patent applications filed by BSP. BLIS and BSP are pleased to report that these negotiations have concluded, with BSP and BLIS agreeing that the patent applications will be jointly owned. This is a positive step forward for both BLIS, BSP and Lactosan, and provides certainty of access for BLIS and its licensees to this market leading technology developed, and contributed to, by BLIS, BSP and Lactosan. As part of this arrangement, BLIS, BSP and Lactosan have released each other of all claims and causes of action arising from the publication of the patent applications.

BLIS would like to thank both BSP and Lactosan for their willingness to engage positively on this matter and the transparent and ethical manner in which both parties have conducted themselves during the course of the negotiations.

BLIS and BSP are also pleased to announce they have renegotiated a five year extension to their existing supply agreement that was scheduled to expire this month.

Ends

For further information, please contact:

Scott Johnson CEO +64 21 488 831

About BLIS Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics

BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS[®] products are sold throughout New Zealand and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found at www.blis.co.nz.

Website: www.blis.co.nz Instagram: @blisprobiotics #blisk12 #blism18 #blisq24 Facebook: @BLISProbiotics

BLIS Technologies Limited: Ground Floor, 399 Moray Place, Dunedin Central 9016, PO Box 2208, Dunedin 9044, New Zealand T:+64 3 474 0988 E: [email protected] W: www.blis.co.nz